A comprehensive view of Complete Response Letters (CRL) / Disapproval. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.
FDA denies approval for Viatris and Mapi Pharma's monthly multiple sclerosis injection GA Depot; Viatris confirms decision will not impact future revenue or new product range
Published:
March 12, 2024
by CE Noticias Financieras
|
FDA rejects Eli Lilly's eczema treatment lebrikizumab due to issues found during inspection at third-party contract manufacturing organization; FDA has rejected three Lilly drugs this year
Published:
October 02, 2023
by FiercePharma
|
Regeneron suffers set-back for release of new version of high-dose Eylea eye-medicine after FDA rejects approval request due to manufacturing issue; FDA raises no safety or efficiency issues, or demand for new trials
Published:
June 28, 2023
by BioPharma Dive
|
FDA rejects Eli Lilly's ulcerative colitis drug mirikizumab due to manufacturing issues; approval in Japan and ongoing review in Europe remain intact
Published:
April 14, 2023
by MedCityNews.com
|
Ask us about our Health Care Sector market view